ACTG REPRIEVE Chosen for ViiV Grant

Congratulations to ACTG REPRIEVE, study A5332, for receiving a ViiV Global HIV and COVID-19 Emergency Response Fund grant! ViiV included REPRIEVE as one of 109 grantees out of over 400 grant applications.